Previous 10 | Next 10 |
Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that the underwriters of its recently closed underwritten public offering of 2,000,000 shares of its common stock have exercised in full their option to purchase an additional 300,000 shares of common stock at the public offering price ...
Castle Biosciences (NASDAQ: CSTL ) has priced its public offering of 2M common stock at $37.00/share, for expected gross proceeds of $74M. More news on: Castle Biosciences, Inc., Healthcare stocks news, , Read more ...
Castle Biosciences, Inc. (Nasdaq: CSTL), announced today the pricing of its underwritten public offering of 2,000,000 shares of its common stock at a price to the public of $37.00 per share. The gross proceeds to Castle Biosciences from the offering, before deducting the underwriting discount...
Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that it has commenced a proposed underwritten public offering of 1,500,000 shares of its common stock. Castle Biosciences also intends to grant the underwriters a 30-day option to purchase up to an additional 225,000 shares of common st...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced a change of the location of its 2020 Annual Meeting of Stockholders to The San Luis Hotel, 5222 Seawall Blvd., Galveston...
Quick Take Castle Biosciences ( CSTL ) went public in July 2019, pricing its IPO shares at $16.00. The firm is commercializing cancer diagnostic and prognostic testing products and services. CSTL has grown revenue and gross profit at an impressive trajectory and the firm expects to launc...
Published in Current Medical Research & Opinion Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the publication of an intended use survey for DecisionDx ...
Castle Biosciences, Inc. (CSTL) Q1 2020 Earnings Conference Call May 11, 2020 04:30 PM ET Company Participants Frank Stokes - Chief Financial Officer Derek Maetzold - Chief Executive Officer Conference Call Participants Max Masucci - Canaccord Genuity Catherine Schulte - Ba...
The following slide deck was published by Castle Biosciences, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Image source: The Motley Fool. Castle Biosciences Inc (NASDAQ: CSTL) Q1 2020 Earnings Call May 11, 2020 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at ...
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...